MLL
VRTX icon

Moody Lynn & Lieberson’s Vertex Pharmaceuticals VRTX Stock Holding History

Moody Lynn & Lieberson’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.1M Sell
56,624
-1,016
-2% -$450K 1.48% 18
2026
Q1 		$25.7M Buy
57,640
+2,648
+5% +$1.23M 1.44% 21
2025
Q4 		$24.9M Sell
54,992
-1,567
-3% -$675K 1.32% 22
2025
Q3 		$22.2M Sell
56,559
-1,518
-3% -$634K 1.19% 24
2025
Q2 		$25.9M Buy
58,077
+822
+1% +$379K 1.49% 22
2025
Q1 		$27.8M Buy
57,255
+32
+0.1% +$14.9K 1.78% 20
2024
Q4 		$23M Sell
57,223
-7,984
-12% -$3.7M 1.41% 24
2024
Q3 		$30.3M Buy
65,207
+8,782
+16% +$4.22M 1.87% 17
2024
Q2 		$26.4M Sell
56,425
-5,547
-9% -$2.41M 1.73% 17
2024
Q1 		$25.9M Buy
61,972
+2,461
+4% +$1.04M 1.74% 18
2023
Q4 		$24.2M Sell
59,511
-10,090
-14% -$3.73M 1.84% 16
2023
Q3 		$24.2M Sell
69,601
-354
-0.5% -$124K 2.07% 14
2023
Q2 		$24.6M Buy
69,955
+1,334
+2% +$449K 1.99% 14
2023
Q1 		$21.6M Sell
68,621
-188
-0.3% -$56.4K 1.94% 19
2022
Q4 		$19.9M Buy
68,809
+19,423
+39% +$5.92M 1.82% 20
2022
Q3 		$14.3M Buy
49,386
+28,484
+136% +$8.2M 1.38% 28
2022
Q2 		$5.89M Buy
20,902
+2,269
+12% +$607K 0.53% 46
2022
Q1 		$4.86M Buy
+18,633
New +$4.42M 0.36% 60
2020
Q3 		– Sell
-14,938
Closed -$4.34M – 210
2020
Q2 		$4.34M Sell
14,938
-10,665
-42% -$2.89M 0.47% 52
2020
Q1 		$6.09M Sell
25,603
-562
-2% -$129K 0.84% 38
2019
Q4 		$5.73M Buy
+26,165
New +$5.3M 0.55% 54
2018
Q1 		– Sell
-23,640
Closed -$3.94M – 216
2017
Q4 		$3.94M Buy
+23,640
New +$3.5M 0.42% 57
2015
Q1 		– Sell
-36,390
Closed -$4.32M – 205
2014
Q4 		$4.32M Buy
+36,390
New +$4.1M 0.62% 59

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Moody Lynn & Lieberson's VRTX Position: Q2 2026 in Review

Moody Lynn & Lieberson reduced its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q2 2026, selling an estimated $450K and leaving 56,624 shares worth $28.1M. The position accounts for 1.48% of the portfolio, ranked #18.

Moody Lynn & Lieberson first reported a position in VRTX in Q4 2014 and has held it in 23 quarters since. The position peaked at $30.3M in Q3 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Moody Lynn & Lieberson held 56,624 shares of Vertex Pharmaceuticals worth $28.1M as of Q2 2026.
  • Moody Lynn & Lieberson sold 1,016 Vertex Pharmaceuticals shares in Q2 2026, an estimated $450K.
  • Vertex Pharmaceuticals made up 1.48% of Moody Lynn & Lieberson's portfolio in Q2 2026, its #18 holding.
  • Moody Lynn & Lieberson first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 23 quarters since.
  • Moody Lynn & Lieberson's Vertex Pharmaceuticals position peaked at $30.3M in Q3 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Moody Lynn & Lieberson's 13F filing for Q2 2026, filed 20 Jul 2026.